Fibroblast Activation Protein Inhibitor Imaging and Therapy in a Patient With Multiple Endocrine Neoplasia Type 2A Syndrome.
Clin Nucl Med
; 47(3): e284-e286, 2022 Mar 01.
Article
en En
| MEDLINE
| ID: mdl-35067538
ABSTRACT
ABSTRACT A patient with multiple endocrine neoplasia type 2A syndrome who had exhausted several surgeries and radiotherapy was referred to nuclear medicine department for theranostic approaches. [68Ga]-DOTATATE PET/CT and [131I]I-mIBG SPECT/CT were performed, but the degree of uptake was insufficient for using the treatment companion of these tracers. Finally, 1 year later, [68Ga]-FAPI-46 PET/CT showed progressive disease with metastases to the lung, liver, bone, and lymph nodes with intense [68Ga]-FAPI-46 uptake. Treatment with [177Lu]Lu-FAPI-46 was done, and the patient tolerated treatment and showed evidence of clinical improvement following therapy.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasia Endocrina Múltiple Tipo 2a
/
Radioisótopos de Yodo
Límite:
Humans
Idioma:
En
Revista:
Clin Nucl Med
Año:
2022
Tipo del documento:
Article